Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1989 Jun;27(6):723-39.
doi: 10.1111/j.1365-2125.1989.tb03434.x.

The benefits of prescription information leaflets (1)

Affiliations
Clinical Trial

The benefits of prescription information leaflets (1)

S Gibbs et al. Br J Clin Pharmacol. 1989 Jun.

Abstract

1. Prescription information leaflets (PILs) giving information about non-steroidal anti-inflammatory drugs (NSAIDs), beta-adrenoceptor antagonists and inhaled bronchodilators were evaluated in three small Hampshire towns, while a fourth, in which no leaflets were distributed, acted as a control. 2. Seven hundred and nineteen (82%) patients prescribed one of these medicines agreed to be interviewed in their homes, 1 to 2 weeks after the medicine had been prescribed. Four hundred and nineteen of them had received leaflets, while 300 received no written information. Two hundred and sixty patients received their leaflets from a pharmacist while 159 were given them by their general practitioner. 3. Patients who received leaflets were better informed about every item of knowledge tested, except for the name of the medicine. Awareness of the side effects showed the greatest improvement, but there was no evidence that these leaflets produced spurious side effects. 4. Much improved levels of satisfaction were recorded amongst patients who received leaflets, especially those for NSAIDs (P less than 0.001) and for beta-adrenoceptor antagonists (P less than 0.01). 5. Subsequently, three hundred and fifty-eight (77%) of the patients prescribed either a NSAID or a beta-adrenoceptor antagonist 1 year earlier responded to a postal questionnaire. The benefits in terms of knowledge and satisfaction were still apparent, although less marked than previously. Of the patients still taking beta-adrenoceptor antagonists 70% had retained their leaflets over the intervening 12 months. 6. Ninety-seven per cent of patients read their leaflet regardless of whether it was distributed by a general practitioner or pharmacist. However, those who obtained it from a pharmacist tended to be more knowledgeable and satisfied. 7. We conclude that patients welcome the idea of receiving PILs. They improve patients' knowledge of how to take their medicines correctly and their awareness of potential side effects. Importantly, patients who receive leaflets are more satisfied than those who do not. These overall benefits justify the use of leaflets on a routine basis.

PubMed Disclaimer

References

    1. Br Med J (Clin Res Ed). 1983 Oct 22;287(6400):1193-6 - PubMed
    1. Lancet. 1983 Mar 26;1(8326 Pt 1):691-6 - PubMed
    1. Soc Sci Med. 1985;20(1):29-37 - PubMed
    1. Br Med J (Clin Res Ed). 1985 Nov 23;291(6507):1483-5 - PubMed
    1. Br J Clin Pharmacol. 1986 Jun;21(6):701-12 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources